Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entospletinib plus corticosteroids as first-line therapy for chronic graft-versus-host disease
2015-004572-30Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic graft-versus-host disease (cGVHD) comparing Entospletinib + systemic corticosteroids with Placebo + systemic corticosteroids (2 arms). Primary endpoint: Best overall response rate by 24 weeks. Started Feb 2016; status: terminated.
02
Drugs
entospletinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2015-004572-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004572-30.